Defuse glioma patients with PTPN1, and AGO2 mutation showed worse overall survival both in the overall group (p = 3.86 × 10−8; Figure 4A) and disease-free/progression-free group (P=2.85 × 10−5; Figure 4B), indicating that PTPN1 and AGO2 may play important roles in diffuse glioma and were related to survival rate. This evidence concerns the gene PTPN1 and central nervous system cancer.